Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25139930 | 1.00 | LMNA (0.48) | LMNAKMT2AALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL18588459 | 1.00 | LMNA (0.48) | LMNAKMT2AALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL18588476 | 0.92 | KMT2A (0.50) | LMNAKMT2AALDH1A1SIGMAR1TSHR | |
| SCHEMBL25139916 | 0.92 | KMT2A (0.50) | LMNAKMT2AALDH1A1SIGMAR1TSHR | |
| SCHEMBL18588458 | 0.92 | KMT2A (0.50) | LMNAKMT2AALDH1A1SIGMAR1TSHR | |
| SCHEMBL18588460 | 0.86 | LMNA (0.42) | LMNAALDH1A1SIGMAR1NAAAGRM4 | |
| SCHEMBL18588464 | 0.86 | LMNA (0.42) | LMNAALDH1A1SIGMAR1NAAAGRM4 | |
| SCHEMBL20879983 | 0.85 | LMNA (0.51) | LMNAKMT2AALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL19849362 | 0.85 | LMNA (0.51) | LMNAKMT2AALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL23252220 | 0.84 | LMNA (0.46) | LMNAKMT2AALDH1A1ALOX15SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | ASCENDIS PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | LMNA 1992/4885KMT2A 4600/4885ALDH1A1 239/4885 |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | LMNA 1914/4885KMT2A 1703/4885ALDH1A1 4509/4885 |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | LMNA 1535/4885KMT2A 2937/4885ALDH1A1 4398/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | LMNA 1914/4885KMT2A 1703/4885ALDH1A1 4509/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | LMNA 187/4885KMT2A 327/4885ALDH1A1 140/4885 |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | LMNA 1535/4885KMT2A 2937/4885ALDH1A1 4398/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | LMNA 3156/4885KMT2A 3136/4885ALDH1A1 1053/4885 |
| US-10980860-B2 | Diagnosis, prevention and treatment of diseases of the joint | TNF, ADAMTS5, ADAMTS1 | LMNA 1817/4885KMT2A 3627/4885ALDH1A1 631/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | LMNA 194/4885KMT2A 320/4885ALDH1A1 143/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | LMNA 3156/4885KMT2A 3136/4885ALDH1A1 1053/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | LMNA 1914/4885KMT2A 1703/4885ALDH1A1 4509/4885 |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | GHRHR, GHSR, GCG | LMNA 1914/4885KMT2A 1703/4885ALDH1A1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.